Neurogene (NGNE) to Release Quarterly Earnings on Monday

Neurogene (NASDAQ:NGNE) is expected to issue its quarterly earnings data before the market opens on Monday, February 17th. Analysts expect the company to announce earnings of ($1.10) per share for the quarter.

Neurogene Trading Down 1.9 %

NGNE stock opened at $18.42 on Friday. The business’s 50-day moving average price is $20.25 and its two-hundred day moving average price is $33.08. Neurogene has a 1-year low of $14.42 and a 1-year high of $74.49.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NGNE. BMO Capital Markets cut their price target on Neurogene from $60.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. Robert W. Baird boosted their price target on Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Neurogene in a report on Monday, November 25th. William Blair restated an “outperform” rating on shares of Neurogene in a report on Tuesday, November 19th. Finally, Leerink Partners boosted their price target on Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurogene currently has an average rating of “Buy” and an average target price of $60.83.

Insider Buying and Selling at Neurogene

In related news, CEO Rachel Mcminn acquired 47,500 shares of the stock in a transaction on Friday, November 22nd. The shares were purchased at an average price of $20.40 per share, for a total transaction of $969,000.00. Following the purchase, the chief executive officer now directly owns 1,297,859 shares in the company, valued at approximately $26,476,323.60. The trade was a 3.80 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Samsara Biocapital Gp, Llc acquired 48,770 shares of the stock in a transaction on Tuesday, November 26th. The shares were bought at an average price of $25.83 per share, for a total transaction of $1,259,729.10. Following the purchase, the insider now owns 1,717,127 shares in the company, valued at approximately $44,353,390.41. This trade represents a 2.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 120,270 shares of company stock worth $2,720,249 over the last 90 days. Company insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.